Collegium Pharmaceutical, Inc.
General ticker "COLL" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.2B (TTM average)
Collegium Pharmaceutical, Inc. does not follow the US Stock Market performance with the rate: -30.4%.
Estimated limits based on current volatility of 2.0%: low 22.49$, high 23.40$
Factors to consider:
- Total employees count: 423 (+18.5%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Opioid abuse regulations, Market competition, Manufacturing issues, Acquisition/divestiture risks, Sales marketing capabilities
- Current price 35.0% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [35.67$, 55.66$]
- 2026-12-31 to 2027-12-31 estimated range: [36.31$, 56.85$]
Financial Metrics affecting the COLL estimates:
- Positive: with PPE of 6.5 at the end of fiscal year the price was neutral
- Positive: 15.29 < Operating cash flow per share per price, % of 21.38
- Positive: 22.58 < Operating profit margin, % of 23.01
- Positive: 12.78 < Shareholder equity ratio, % of 18.21 <= 25.20
- Positive: Industry inventory ratio change (median), % of -0.31 <= 0
- Positive: Inventory ratio change, % of -0.43 <= -0.37
- Positive: Interest expense per share per price, % of 5.34 <= 10.35
- Negative: Investing cash flow per share per price, % of -4.13 <= -2.60
Short-term COLL quotes
Long-term COLL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $566.77MM | $631.45MM | $780.57MM |
| Operating Expenses | $399.81MM | $461.55MM | $600.93MM |
| Operating Income | $166.96MM | $169.90MM | $179.64MM |
| Non-Operating Income | $-91.23MM | $-71.33MM | $-87.02MM |
| Interest Expense | $83.34MM | $73.97MM | $82.31MM |
| Income(Loss) | $75.73MM | $98.57MM | $92.62MM |
| Taxes | $27.58MM | $29.38MM | $29.75MM |
| Net Income(Loss)* | $48.16MM | $69.19MM | $62.87MM |
| Stockholders Equity | $195.43MM | $228.84MM | $301.68MM |
| Inventory | $32.33MM | $35.56MM | $40.91MM |
| Assets | $1,143.31MM | $1,663.59MM | $1,656.83MM |
| Operating Cash Flow | $274.75MM | $204.98MM | $329.32MM |
| Capital expenditure | $0.46MM | $1.65MM | $1.74MM |
| Investing Cash Flow | $-70.81MM | $-287.76MM | $-63.53MM |
| Financing Cash Flow | $-140.18MM | $-60.60MM | $-110.25MM |
| Earnings Per Share** | $1.43 | $2.14 | $1.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.